Introduction:
The pharmaceutical industry in China has been rapidly expanding, with a focus on complex generic and biosimilar development. With the increasing demand for affordable healthcare options, Chinese companies have been stepping up their game to compete in the global market. In 2020, China’s pharmaceutical exports reached $40.5 billion, demonstrating the country’s growing presence in the industry.
Top 10 Complex Generic & Biosimilar Developers in China:
1. Sinopharm Group Co., Ltd.
Sinopharm Group is one of China’s largest pharmaceutical companies, specializing in complex generic and biosimilar development. With an annual production volume of over 100 million units, Sinopharm has a significant market share in China and is expanding its presence globally.
2. Shanghai Pharmaceuticals Holding Co., Ltd.
Shanghai Pharmaceuticals Holding is a key player in the Chinese pharmaceutical industry, focusing on the development of complex generics and biosimilars. The company’s exports have been steadily increasing, reaching $2.5 billion in 2020.
3. Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui Medicine is a leading developer of complex generics and biosimilars in China. With a market share of 15% in the country, the company is known for its high-quality products and innovative research.
4. Fosun Pharma
Fosun Pharma is a major player in the Chinese pharmaceutical market, with a focus on complex generics and biosimilars. The company’s trade value reached $3.2 billion in 2020, making it one of the top exporters in the industry.
5. China Resources Pharmaceutical Group Limited
China Resources Pharmaceutical Group is a well-established pharmaceutical company in China, specializing in complex generics and biosimilars. With a production volume of 80 million units per year, the company has a strong presence in both domestic and international markets.
6. CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a leading developer of complex generics and biosimilars in China. The company’s market share has been steadily increasing, reaching 10% in 2020. With a focus on innovation and research, CSPC is poised for further growth in the coming years.
7. Sino Biopharmaceutical Limited
Sino Biopharmaceutical is a key player in the Chinese pharmaceutical industry, focusing on the development of complex generics and biosimilars. The company’s exports have been growing steadily, reaching $1.8 billion in 2020.
8. China National Pharmaceutical Group Corporation (Sinopharm)
Sinopharm is a state-owned enterprise and one of the largest pharmaceutical companies in China. With a focus on complex generics and biosimilars, the company plays a crucial role in the country’s healthcare sector. Sinopharm’s production volume exceeds 120 million units per year, making it a major player in the industry.
9. Zhejiang Hisun Pharmaceutical Co., Ltd.
Zhejiang Hisun Pharmaceutical is a prominent developer of complex generics and biosimilars in China. The company’s market share has been steadily increasing, reaching 8% in 2020. With a strong focus on research and development, Zhejiang Hisun is well-positioned for future growth.
10. 3SBio Inc.
3SBio Inc. is a leading biotechnology company in China, specializing in complex generics and biosimilars. The company’s trade value reached $1.5 billion in 2020, highlighting its strong presence in the global market.
Insights:
The pharmaceutical industry in China is witnessing a significant shift towards complex generics and biosimilars, driven by the increasing demand for affordable healthcare options. Chinese companies are investing heavily in research and development to stay competitive in the global market. By 2025, the global biosimilars market is projected to reach $35 billion, offering immense growth opportunities for Chinese developers. With a strong focus on innovation and quality, China is poised to become a key player in the complex generics and biosimilars market in the coming years.
Related Analysis: View Previous Industry Report
